MS SB2830

Expands the definition of "eligible patient" under Mississippi's Right-to-Try Act to include persons with traumatic injuries in addition to debilitating disabilities, terminal illnesses, or life-threatening illnesses.

Adds "adult autologous mesenchymal stem cell" to the definition of investigational treatments available under the Right-to-Try Act alongside investigational drugs, biological products, and devices.

Requires that investigational treatments, including adult autologous mesenchymal stem cells, must have successfully completed phase one of a clinical trial, been described in an FDA/NIH approved protocol, been approved by an institutional review board, or successfully completed a safety study.

Prohibits state agencies and regulatory boards from revoking, failing to renew, or taking action against a physician's or pharmacist's license based solely on recommending eligible patients access to investigational treatments covered by the Act.

Provides liability immunity to manufacturers, prescribers, dispensers, and health care facilities from civil liability for losses or injuries arising from investigational treatments used under the Act, except in cases of gross negligence or willful misconduct.